succinobucol

Description: Succinobucol (formerly known as AGI-1067, AGZ-1067, Probucol monosuccinate, succinyl ester of probucol) is a a lipid-lowering compound and a phenolic antioxidant with anti-inflammatory and antiplatelet effects. Succinobucol inhibits TLR4 ligand (LPS)-induced activation of ASK1 and the downstream p38 and JNK MAP kinases, which could inhibit ASK1-JNK/p38-dependent gene expression of proinflamamtory molecules. Inhibition of both p38 and JNK by AGI-1067 occurred in a concentration-dependent manner with an IC50 value under 5 uM. AtheroGenics reports positive results from ANDES Phase 3 Clinical Trial (NCT00066898) of Succinobucol.

References: Mol Neurobiol. 2016 Mar; 53(2):1280-95; Platelets. 2017 May; 28(3):295-300.